Abstract: Chronic liver disease (CLD) is a major health problem worldwide. Non-alcoholic fatty liver disease (NAFLD), chronic hepatitis C (CHC), chronic hepatitis B (CHB), and alcoholic liver disease (ALD) are the most common etiologies of CLD. Liver biopsy is the gold standard for assessment of liver fibrosis, however, it is an invasive method. This review attempts to evaluate the usefulness of serum adiponectin, serum leptin, serum ferritin, serum transforming growth factor-β1 (TGF-β1), and serum platelet derived growth factor-BB (PDGF-BB) as non-invasive markers in the diagnosis of liver fibrosis/cirrhosis. A systematic search in MEDLINE, Web of Science, Scopus, and local databases was performed to identify articles published in English or Persian as of November 2017. Studies conducted among CLD patients, with biopsy proven fibrosis/cirrhosis, and providing sufficient details of patients' clinicopathological characteristics were included. In the 95 studies included, there were a total of 15,548 CLD patients. More than 83% of studies were carried out in Asia and Europe. The relationship between liver fibrosis/ cirrhosis and serum levels of ferritin, adiponectin, leptin, TGF-β1, and PDGF-BB was assessed in 42, 33, 27, nine, and three studies, respectively. Serum levels of the markers, particularly ferritin, could successfully predict liver fibrosis/cirrhosis, however, these data might not be clinically replicated and further studies are needed.
Background
Chronic liver disease (CLD) refers to disease of the liver which involves a process of progressive destruction and regeneration of the liver parenchyma, leading to fibrosis, cirrhosis, and hepatic insufficiency. Regardless of geographical differences, CLDs have a high prevalence worldwide [1, 2] . The most prevalent etiologies of CLD are hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD). All these diseases can cause stages of liver fibrosis or cirrhosis [2] .
NAFLD have become a serious health concern due to the rising prevalence of obesity and type 2 diabetes mellitus [3] . Currently, NAFLD and NASH are believed to be the most common cause of CLD and liver fibrosis [4] . According to epidemiological studies, it is estimated that 3%-34% of the general population have NAFLD and 2%-5% have NASH [5, 6] . It is approximated that annually three to four million new cases of HCV infection are diagnosed. Around 71 million people are chronically infected with HCV worldwide and 399,000 deaths are reported due to all HCV related causes, mostly from cirrhosis and hepatocellular carcinoma (HCC) each year [7] . HBV infection is a major health problem and it is estimated that two billion are infected throughout the world. There are nearly more than 257 million people suffering from chronic HBV infection, which resulted in 887,000 deaths in 2015, mostly from complications such as cirrhosis and HCC [7] . Alcohol consumption has been identified as a major risk factor for all liver diseases and is significantly associated with cirrhosis. Around 47.9% of cirrhosis deaths (46.5% of women and 48.5% of men) are related to ALD [8] .
Chronic damage to the hepatocytes and activation of the hepatic stellate cells (HSCs), also known as perisinusoidal cells, Ito cells, lipocytes and fat-storing cells, is believed to be the beginning of the insidious process of the liver fibrosis. Liver fibrosis is the result of repeated injury and wound-healing response of the liver, and the consequent accumulation of extracellular matrix (ECM) proteins. Most related complications occur when cirrhosis develops [2, 9] . The necessity of long-term monitoring of CLD, and also the requirement of liver biopsy as the gold standard for the diagnosis and assessment of the necroinflammatory grade and stage of fibrosis has led to some restrictions for clinicians and researchers. The invasive nature of biopsy, including possible complications such as pain and hemorrhage, technical errors, resampling limitations, the presence of some clinical conditions such as ascites and coagulation disorders, and variations between decisions made by different pathologists could justify that non-invasive, reliable, and simple sampling methods are needed for the assessment of liver fibrosis [10, 11] .
Recently, several non-invasive tests have been made available for the assessment of liver fibrosis, such as aspartate transaminase to platelet ratio index, enhanced liver fibrosis, FIB-4, FibroTest, Forns index, FibroScan, and a significant hepatic fibrosis index [12] [13] [14] . Serum markers could be useful in directly and indirectly evaluating liver function and liver fibrosis [15] . A number of the serum markers which are directly associated with liver fibrogenesis and ECM degeneration, including hyaluronic acid, tissue inhibitor of metalloproteinase type 1 (TIMP-1), YKL-40, collagen subtypes, cytokines, and chemokines, are under investigation, and some have been previously tested [12, 16] . It is assumed that cytokines and adipokines play central roles in the progression from chronic liver injury to fibrosis/cirrhosis. Transforming growth factor-β1 (TGF-β1), platelet derived growth factor-BB (PDGF-BB), leptin, adiponectin and ferritin are multifunctional factors and are involved in inflammation, immune system modulation, and wound healing processes. Therefore, these molecules could affect the development and progression of liver fibrosis [17, 18] . Accordingly, we are going to focus on the five markers which may be directly or indirectly linked to the presence or extent of liver fibrosis or cirrhosis. A great number of studies have investigated the possible association of serum levels of these markers with liver fibrosis or cirrhosis, however, a systematic review or metaanalysis is needed to clarify the clinical importance of the markers. This systematic review provides an overview of the original studies carried out in the field. Moreover, this review discusses the findings and different aspects of the studies in order to better understand the clinical usefulness of the markers and present updated information to the field.
Methods

Literature search
Initially 13,649 records were obtained from comprehensive databases including Web of Sciences, Scopus, MEDLINE (by PubMed), and Science Direct, in addition to local databases including Scientific information database, Elmnet, Magiran, Irandoc, Barakat Know ledge Network System (IranMedex), and IslamMedex using various combination of search keywords including "liver fibrosis", "hepatic fibrosis", cirrhosis, leptin, adiponectin, ferritin, "platelet derived growth factor", "transforming growth factor", PDGF, TGF, and serum. The search was not limited by publication time and it ended at November 2017. The search was limited to English and Persian publications. The Medical subject headings database was used as the terminological search filter. The following query was formatted and used in different databases by their requirements:
("liver fibrosis" OR "hepatic fibrosis" OR cirrhosis) AND (leptin OR adiponectin OR ferritin OR "platelet derived growth factor" OR "transforming growth factor" OR TGF OR PDGF) AND serum
The search was supplemented by manual searching of other sources including conference proceedings, reference lists, researchers in field, and related citations.
Inclusion and exclusion criteria
All the observational clinical studies which compared serum levels of leptin, ferritin, adiponectin, PDGF-BB, and TGF-β1 by different stages of fibrosis in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC), NAFLD/NASH, and ALD were eligible for this systematic review. Studies which aimed at diagnosing fibrosis/cirrhosis in CLD using the markers were eligible as well.
In detail, studies were included in the systematic review if: (1) they were original full-text publications or abstracts containing sufficient data; (2) they included patients with biopsy-proven fibrosis/cirrhosis; (3) they made comparison between different stages of fibrosis for serum levels of leptin, adiponectin, ferritin, PDGF-BB, and TGF-β1 or they aimed at diagnosing fibrosis/cirrhosis in CLD using these markers.
Studies were excluded from the systematic review if: (1) they included patients who had co-infection with human immunodeficiency virus (HIV), HBV, and HCV; (2) they included patients with CLDs other than NAFLD/ NASH, ALD, CHC, and CHB (e.g. autoimmune hepatitis); (3) study sample size was less than 30; (4) they measured candidate markers in specimens other than serum; (5) they did not provide sufficient details about patients demographics (e.g. gender, age, etc.); (6) they included patients with unspecified cause of fibrosis/cirrhosis; (7) they were reviews, letter to editors, case reports, hypothesis, book chapter/section, editorials, animal model/cell line studies; (8) they included patients under therapeutic intervention; (9) they included patients with underlying diseases (e.g. cardiovascular diseases); (10) they included post-transplant patients.
Results and discussion
Literature search
Initially 13,649 records were obtained from comprehensive and local databases using various combinations of the above mentioned terms and keywords. Moreover, 158 citations were added from other aforementioned sources. To summarize the identification, screening, eligibility and final selection procedure for included articles in the systematic review, a flowchart was drawn according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [19] . Two hundred and twelve articles were initially selected and finally, 95 articles were included in the systematic review ( Figure 1) .
Characteristics of included studies
The 95 included studies were published between 1996 and 2016. Cross-sectional studies (n = 53), case-control studies (n = 34), cohort studies (n = 5), and therapeutic interventions (n = 3) were the most frequent study designs, respectively. Of the 15,548 CLD patients who were enrolled in the studies, 9,103 were male and 6,445 were female. The main characteristics of the included studies, the main demographics, clinical, and biochemical features of the patients and also the results of the statistical analyses were extracted and double checked by an investigator and then summarized in Table 1 . Thirty-seven studies were conducted in Asia, 41 in Europe, 12 in America, and five in Australia. Forty-three studies were carried out among patients with CHC, 34 among patients with NAFLD/NASH, nine among patients with CHB, two among patients with ALD, and seven among groups of patients with CLD of different etiologies. Metavir, Brunt, Ishak, Kleiner, Scheuer, and Knodell were the most popular fibrosis scoring systems, which were used in 19, 19, 14, 14, 11 , and eight studies, respectively. Serum levels of leptin, adiponectin, PDGF-BB, TGF-β1 and ferritin were measured using enzyme linked-immunosorbent assays (ELISAs) in 49 studies and radioimmunoassays (RIAs) in nine studies. Thirty-seven studies used spectrophotometry, chromatography, colorimetric and other commercially available methods for measurement of the markers. Details of measurement methods were not mentioned in some studies.
Transforming growth factor-β and non-invasive assessment of liver fibrosis
TGF-β is a multifunctional growth factor and plays important roles in cell growth and differentiation, immune regulation and matrix synthesis [114] . Three different isoforms of TGF-β including TGF-β1, TGF-β2, and TGF-β3 have been identified in mammalians' tissue. TGF-β1 is found to be the predominant isoform of TGF-β. All TGF-β isoforms are synthesized and secreted in a latent form and must be activated to exert their biological effects. This latent inactive TGF-β complex consists of a TGF-β homodimer, a latency associated peptide, and a latent TGF-β-binding protein (LTBP). Processing from the latent form to the biologically active form could be induced by changes in ionic strength, changes in pH, or proteolytic enzymes. Only the biologically active form of TGF-β1 is immunoreactive and could be detected by immunoassay [115, 116] .
TGF-β blocks matrix degradation by decreasing and increasing of the synthesis of proteases and the levels of protease inhibitors, respectively [117] . Additionally, TGF-β induces deposition of extracellular matrix in the site of injury and it can cause scarring and fibrosis [118] . Induction of apoptosis mediated by TGF-β in hepatocytes was found to be connected with liver cirrhosis [119] . TGF-β1 mediates HSCs activation and transformation in conjunction with other growth factors such as PDGF-BB [23] .
In this systematic review, nine studies which investigated the relationship between TGF-β1 and liver fibrosis/ cirrhosis were eligible according to the inclusion criteria. Three studies by Kirmaz et al., Nelson et al., and Neuman et al. in patients with CHC indicated that there is positive correlation between fibrosis stages and the serum levels of total TGF-β1. However, in the case of biologically active TGF-β1 such a correlation was not observed. The study by Nelson et al. evaluated serum TGF-β1 within 12 months from liver biopsy, while the study by Neuman et al. provided sequential data on liver biopsy that were used to ascertain the serum TGF-β1 predictive value for liver fibrosis progression [20] [21] [22] . In another investigation among patients with NASH or CHC such correlation was not observed [25] . Further, in two studies serum TGF-β1 was reported as a predictor of progressive liver fibrosis [22, 26] . On the other hand, the findings of three studies conducted among patients with CHB showed that there is no correlation between the serum TGF-β1 and stage of fibrosis. No significant difference was observed when the mean concentrations of total TGF-β1 was compared by stages of fibrosis [20, 23, 24] . Palekar et al. found no significant difference of mean serum levels of TGF-β1 between simple steatosis and NASH (at different stage of fibrosis); while serum levels of the TGF-β1 were significantly higher among non-mild fibrosis when compared to severe fibrosis [27] . Receiver operating characteristic (ROC) curve analysis in two studies by Palekar et al. and Zoheiry et al. showed that the serum TGF-β1 could significantly predict advanced liver fibrosis. However, another study in patients with CHB showed that advanced fibrosis could not be predicted by serum TGF-β1 [24, 27, 28] . More details of results and characteristics of the studies are presented in Table 1 . In order to measure the total amount of TGF-β1 (latent form + biologically active form) in serum or other biological fluids by immunoassay, the sample must be treated by an acid solution to remove the proteins attached to the latent form of TGF-β1 (e.g. LTBP). On the other hand, to measure the biologically active form, the sample must be applied to the system without acid treatment. It has been demonstrated that the concentrations of the latent form is much more than the concentrations of the biologically active form in serum or plasma. The latent form of TGF-β1 has a half-life of 100 min in plasma, and thus, each measurement may be a snapshot at that point of time [25] . Given this, changes in the total amount of TGF-β1 could not reflect the extent of liver fibrosis at a certain point of time. It is believed that simple fatty liver is not so benign as previously thought, because TGF-β1 is detectable in this condition. Therefore, increased serum TGF-β1 in fatty liver could be a consequence of excess lipid deposition and/or initial inflammation [25] , nevertheless, decreased levels of TGF-β1 in NASH patients with advanced liver fibrosis has remained a controversial issue [22] . Increased serum levels of TGF-β1 in advanced stages of fibrosis might refer to the chronic background of the disease in patients with chronic viral hepatitis (CVH) [120, 121] . The significant positive correlation between serum TGF-β1 and stage of fibrosis, and also higher levels of the cytokine in patients with CHC when compared to patients with CHB may indicate different pathogenesis of the diseases. For this connection, findings of an investigation in 2004 showed an up-regulated TGF-β1 expression in response to HCV core antigen when compared with hepatitis of other etiologies [122] . It has been speculated that host genetic diversity could affect the production of TGF-β and a high producing TGF-β genotype was detected in 2000 by Powell et al. [123] . It is noteworthy that no significant difference has been observed in TGF-β levels by HCV genotypes [22] . These data support the idea of the central role of TGF-β in the progression to chronic disease. TGF-β may cause more serious damage to the liver in patients with CHC and consequently may be related to poor prognosis in these patients.
Platelet derived growth factor-BB and non-invasive assessment of liver fibrosis
PDGF-BB is a growth factor in which its biosynthesis is stimulated by TGF-β [124] . Recently, it has been shown that PDGF-BB signaling strongly promotes HSCs activation and induces phenotypic changes, followed by collagen deposition and fibrogenesis. In the liver, PDGF-BB levels are associated with fibrosis of different etiologies [125, 126] . Moreover, it is supposed that TGF-β1 governs development of the hepatic fibrosis by inducing the mitogenic effect of PDGF-BB [127] .
Out of the three studies that discussed the clinical importance of PDGF-BB in the prediction of fibrosis or cirrhosis, two studies were conducted among patients with CHB and one study was among patients with CHC. Zhou et al. reported a strong negative correlation between fibrosis stages and serum PDGF-BB, however, Zhang et al. found a positive correlation in patients with CHB [18, 23] . In accordance with Zhou et al., the study among patients with CHC reported that serum PDGF-BB negatively correlated with fibrosis stages and decreased PDGF-BB was associated with cirrhosis [29] . More details of results and characteristics of the studies are presented in Table 1 .
It appears that serum levels of PDGF-BB tend to be decreased during progression of liver fibrosis and in cirrhosis it reaches its lowest level. The extrahepatic concentration of PDGF-BB is believed to be related to the platelet count, and therefore, decreased serum levels of PDGF-BB could be justified by the decreasing platelet count during progression of liver fibrosis in patients with CHB and CHC [126, 128, 129] . The positive correlation reported by Zhang et al. might be due to the small sample size compared to the others, differences in the response of immune system to the injury or extent of the liver damage in those patients.
Leptin and non-invasive assessment of liver fibrosis
Leptin, an important adipokine, plays a central role in the regulation of lipid accumulation, inflammation and immune system functions by paracrine or endocrine mechanisms [17] .
In addition to the role of leptin in the regulation of food intake and energy expenditure, its important role in liver fibrogenesis has also been demonstrated. Briefly, leptin participates in modulating the response to the injury by increasing the expression of type I procollagen and potentiates the effect of TGF-β through binding to its receptor on HSCs, up-regulation of TIMP-1, activating MAP kinase and PI3K/Akt signaling pathways, amplification of inflammatory responses mediated by NF-κB in HSCs, and stimulation of angiogenesis through up-regulation of the vascular endothelial growth factor in HSCs [130] [131] [132] [133] .
Of 28 studies which investigated the possible association of serum leptin with liver fibrosis/cirrhosis, 13 were carried out in patients with CVH, 12 in patients with NAFLD, two in patients with ALD, and one in patients with NAFLD or CVH. Eight studies conducted in patients with NAFLD used univariate analysis and found no significant association; however, a study in Greece reported a significant association after stratifying results by gender [30] [31] [32] [33] [34] [35] [36] [37] [38] . Multivariate analysis revealed that serum leptin could not predict any stage of liver fibrosis or cirrhosis in NAFLD [39] [40] [41] [42] . Out of the 12 studies among patients with CVH, seven studies found no significant association between serum leptin and liver fibrosis/cirrhosis [43] [44] [45] [46] [47] [48] [49] [50] . Results of multivariate analysis in patients with CVH showed that serum leptin could not predict stage of liver fibrosis as well [51] [52] [53] . Despite the fact that three studies found a positive correlation between serum leptin and liver fibrosis/cirrhosis [51, 53, 54] , two studies did not find such a correlation [47, 55] . A study in Greece showed that the etiology of CLD may affect the serum leptin levels [38] . Results of the ROC curve analysis showed poor diagnostic accuracy of the serum leptin [52, 53] . More details of results and characteristics of the studies are presented in Table 1 .
Two studies carried out in patients with ALD had opposite results. The study by Nicolas et al. among men reported no significant association [56] , however, the other study by Naveau et al. among both genders found a significant association using both univariate and multivariate analyses [57] . This controversy may be attributed to the study populations. Indeed, the first study by Nicolas et al. was conducted among alcoholics with compensated cirrhosis. Moreover, the larger sample size and inclusion of female patients in the second study might have affected the findings.
It appears that serum levels of leptin may not be significantly affected by the origin of the study population or the etiology of the CLD. However, the serum levels of leptin seem to be affected by patients' age and gender and percentage of body fat. Therefore, the effects of these factors should be adjusted in future studies. Additionally, the categorization of quantitative variables could affect the results of statistical analyses and must be considered.
Adiponectin and non-invasive assessment of liver fibrosis
Besides the role of adiponectin in carbohydrates and lipid metabolism, its hepatoprotective and anti-inflammatory actions are also well established [134] . Modulation of the activated phenotype of HSCs is found to be the main mechanism by which adiponectin mediates its effects in liver wound healing procedures [135] . Adiponectin suppresses the proliferation and migration of HSCs stimulated with PDGF-BB. Also, adiponectin attenuates the effect of TGF-β1 on the expression of fibrogenic genes such as the connective tissue growth factor [136] . Hence, a mutual regulation of leptin and adiponectin appears with activated phenotype of the HSCs [137] .
Thirty-three studies discussed the possible relationship between serum adiponectin and liver fibrosis/cirrhosis. Four studies were conducted among patients with CHB and 14 among patients with CHC. Thirteen studies were carried out in patients with NAFLD and two studies in patients with CLD of different etiologies. Two studies among patients with CHB found no correlation between serum adiponectin and the stage of liver fibrosis [47, 58] . The remaining two studies by Hui et al. and Liu et al. reported a significant association between the increased serum adiponectin and advanced liver fibrosis/cirrhosis using multivariate and univariate analyses, respectively [59, 60] .
However, six studies among patients with CHC showed no significant correlation between serum adiponectin and fibrosis stage [61] [62] [63] [64] [65] [66] while two studies reported a significant positive correlation [53, 67] . Interestingly, findings of a study in Egypt showed a significant negative correlation between serum adiponectin and liver fibrosis [68] . No significant relationship was seen when univariate analysis was used to assess the association of serum adiponectin with liver fibrosis/cirrhosis [45, 49, 69] . Results of the multivariate and ROC curve analyses used in three studies [53, 70, 71] are summarized in Table 1 .
Of the studies in patients with NAFLD, eight studies assessed the relationship using univariate analysis. Except for a study by Shimida et al. in Japan [72] , the others could not find any significant relationship between serum adiponectin and liver fibrosis [27, 30-32, 35, 36, 73] . Two studies assessed the correlation between serum adiponectin and liver fibrosis. In the study by Savvidou et al., the adiponectin concentrations were normally distributed after a logarithmic transformation and then, the correlation was assessed and a significant negative correlation was observed [74] . In contrast, another study reported no significant correlation [75] . It is interesting to note that multivariate analysis showed no significant results [40, 76] , although an investigation in the US reported the usefulness of decreased serum adiponectin in the diagnosis of advanced fibrosis [34] .
Two studies enrolled patients with CLD of different etiologies. A study by Liew et al. which included patients with CHC, patients with CHB, and patients with NAFLD showed a significant negative correlation between serum adiponectin and stage of liver fibrosis [77] . However, the second study reported a significant association between the increased serum adiponectin and advanced liver fibrosis [38] . The latter study obtained the results after conducting statistical analysis among men and women separately to control the effect of the gender of patients. They stated that the etiology of CLDs and gender could affect the serum concentrations of adiponectin. More detailed results and characteristics of the studies are presented in Table 1 .
It seems that in contrast to serum leptin, serum levels of adiponectin could be affected by the etiology of CLD and that decreased and increased levels of this adipokine could predict advanced liver fibrosis in NAFLD and CVH, respectively. Regarding the inverse correlation between serum adiponectin and BMI, percentage of body fat, serum triglycerides and fasting insulin, the result could be affected by these factors in patients suffering from metabolic syndromes. Thus, the results should be interpreted with caution. In addition, categorization of the quantitative variables included in the analyses could affect the results and must be considered.
Ferritin and non-invasive assessment of liver fibrosis
In addition to the role of ferritin in iron metabolism, it could also affect the inflammatory response, angiogenesis, and suppression of cell mediated immunity [138] . Ferritin is speculated to be a pro-inflammatory signaling molecule in HSCs. It activates PI3K and MAP kinase pathways and finally activates NF-κB which results in the up-regulation of the expression of pro-inflammatory cytokines such as interleukine-1-β and inducible nitric oxide synthase [139] . Interestingly, the binding of ferritin to its receptor on activated HSCs is believed to be responsible for enhanced production of collagen and liver fibrosis [138] . As a clinical tool, serum ferritin is applied for several diagnostic panels and recently has been used for the prediction of cirrhosis [138] .
Forty-two studies assessed the possible link between liver fibrosis/cirrhosis and serum ferritin. Twenty studies were carried out among patients with NAFLD, 19 among patients with CHC, two among patients with CHB, and one among patients with NAFLD or CHC. Nine studies in patients with NAFLD used univariate analysis to assess the association. Five studies found no association [30, 35, [78] [79] [80] and four studies reported a significant association [72, [81] [82] [83] . The majority of studies that used multivariate analysis reported increased levels of the serum ferritin associated with advanced liver fibrosis [84] [85] [86] [87] [88] [89] [90] [91] , although, a study by Chitturi et al. found no association [39] . The correlation analysis showed a significant positive correlation between the serum ferritin and liver fibrosis [92, 93] . Interestingly, in two big studies by Angulo et al. and Yoneda et al., results of ROC curve analysis showed that serum ferritin could not diagnose any stage or combined stages of liver fibrosis [88, 89] . However, a study in 2011 which excluded cirrhotics from the analyses claimed that the increased serum ferritin could successfully diagnose the presence of liver fibrosis [86] . It seems that these opposite results are affected by the sample size or variables included in the analyses.
Of the studies among patients with CHC, four studies used univariate analysis and two studies found a significant relationship between increased serum ferritin and advanced liver fibrosis/cirrhosis [94, 95] . However, two studies observed no association [96, 97] . There were controversies in the correlation analysis results [54, [98] [99] [100] [101] [102] and they are summarized in Table 1 . Additionally, there were controversies in the results of multivariate analyses and most of them reported that increased serum ferritin can predict advanced liver fibrosis in CHC [99, [103] [104] [105] [106] [107] , although, some studies did not find such an association [108] [109] [110] [111] . Results of the ROC curve analysis revealed poor accuracy of serum ferritin for the diagnosis of advanced fibrosis in CHC [94] . Interestingly, the study by Fernandez et al. showed that increased serum ferritin among CHC patients with a history of alcohol consumption could predict faster progression of liver fibrosis [99] . Obviously, alcohol and iron have toxic effects on the liver and it was demonstrated that alcohol consumption can cause disruption to the iron metabolism and be reflected in iron indexes such as elevated serum iron, ferritin, and transferrin saturation [140] [141] [142] [143] . Therefore, this finding could be due to increasing oxidative stress and cell damage related to alcohol and iron toxicity together. Moreover, the elevated serum ferritin may be caused by chronic inflammation and then cause faster progression of fibrosis [138, 144, 145] .
Of the two studies among patients with CHB, the study by Rajabali et al. indicated a significant positive correlation between liver fibrosis and serum ferritin [112] . The other study by Chook et al. found no difference between Categorizing of variables included in the study could also be considered as a factor which affects the statistical test results and conclusion.
f It is a ranking based on the number of the studies for each marker, sample size of the studies and also statistical analyses used for assessment of the relationships. This ranking might be applicable in future clinical studies. The highest rank was considered as five pluses (++ + + +).
cirrhotics and non-cirrhotics in terms of the mean serum ferritin [113] . An investigation among patients suffering from CHC or NAFLD assessed the correlation between liver fibrosis and serum ferritin. In female patients with NAFLD, a significant negative correlation was observed, however, such a correlation was not observed in other groups [25] .
More detailed results and characteristics of the studies are presented in Table 1 . It seems that the origin of study population, etiology of CLD, and patients' demographics may not significantly affect serum ferritin. Nevertheless, the effect of genetic disorders associated with hyperferritinemia or other common clinical conditions such as iron deficiency anemia and also variations between individuals' immune system should be adjusted. Additionally, the differences between results of the studies may arise from the categorization of variables included in the analyses. For instance, some studies compared serum ferritin by stages of fibrosis, some compared between cirrhotics and non-cirrhotics, some compared between non-mild fibrosis and advanced fibrosis, and some excluded special groups of patients from the analyses. In the same way, serum ferritin could also be classified as a continuous quantitative variable or a categorical variable.
Cytokines, adipokines and liver fibrosis
Generally, it is believed that to progress from chronic liver injury to fibrosis and cirrhosis, cytokines, adipokines, growth factors, and other biological mediators play pivotal roles. TGF-β1, PDGF-BB, leptin and ferritin have inflammatory and fibrogenic effects on different cell types, particularly HSCs, during liver fibrogenesis [146] . TGF-β1, PDGF-BB, leptin, and ferritin induce the production and accumulation of ECM which play a crucial role in the liver fibrogenesis [146] . The biosynthesis and mitogenic effects of PDGF-BB are induced by TGF-β1 [124, 127] . Leptin potentiates the effect of TGF-β1 on HSCs; however, adiponectin appears as an anti-fibrogenic and antiinflammatory adipokine and attenuates the effects of TGF-β1 and PDGF-BB in fibrogenesis [131, 134, 136] . Adiponectin, leptin, ferritin, TGF-β1, and PDGF-BB involve three major signaling pathways including MAP kinase, PI3K/Akt, and NF-κB in different cell types involved in fibrogenesis, and further exploration could be useful in discovering drugable targets to prevent progression of the liver fibrosis. Further, angiogenesis and collagen production are two critical events which influence the extent and severity of the disease and might be applicable as targets for treatment [146] . A list of candidate proteins, involved cell types and signaling pathways, possible changes in the serum markers in fibrosis/cirrhosis and their relevance to the disease, and factors that might affect the results of biomarkers examination are summarized in Table 2 .
Measurement methods of serum markers
The ELISA and the RIA are two commonly used immunoassay approaches in clinical and research laboratories. In the current review, these two approaches were the most frequently used assays for measurement of the candidate serum biomarkers.
Immunoassays, either for clinical or research uses, for both the qualitative and quantitative measurement of small molecules and larger peptides and proteins are available. Most of the cytokines and adipokines could be measured by extremely sensitive immunoassays which can detect a very small amount of analyte in the biological fluid (e.g. 0.1 pg/mL) [147] . RIA has a high sensitivity and a low background effect because of its detection system (i.e. γ counter). However, it has some disadvantages such as the cost of equipment and reagents, short shelf-life of radiolabeled compounds, and the problems related to the disposal of radioactive waste. In the ELISA method, the lower sensitivity and background effect may cause erroneous results. A part of these problems could be attributed to its detection system. Visible spectrophotometry, used in ELISA readers, has some advantages such as costeffectiveness, ease of use, and revealing contaminants, although, this method could be affected by temperature, pH, impurities, and contaminants which lead to inaccurate results. It should be noted that most of the problems with ELISA can be handled by an experienced technician [147, 148] . Of the other rarely used immunoassays in the included studies, we can refer to the microparticle enzyme immunoassay (MEIA) and chemiluminescence immunoassay (CLIA) which have very high sensitivity and specificity and are also faster compared to ELISAs and RIAs. MEIA and CLIA do not have the disadvantages of the RIA and ELISA, but they are expensive methods [149] . It seems that selection of a detection method for the measurements could be mainly depending on the nature and concentration of the analyte, optimum operating condition, and cost-effectiveness of the method.
Strengths and limitations
Our study has some limitations. We only included articles published in English and Persian languages and it may have resulted in a language bias. However, it is supposed that restricting the systematic review to English language articles has a minor effect on the conclusion [150] . We did not aim to do meta-analysis owing to the fact that very few studies reported sensitivity, specificity, negative and positive predictive values, and diagnostic accuracy for the aforementioned markers among patients with CLD of different etiologies. Moreover, variations in the study populations and methods used to measure the serum biomarkers and also variations in definition and staging of the liver fibrosis and cirrhosis dissuaded us from pooling the studies and doing a meta-analysis. Our study has some strength. We applied rigorous exclusion criteria to minimize the effects of confounding factors. Additionally, we reviewed all the studies about potential predicting serum markers of fibrosis or cirrhosis in the patients with CLD of different etiologies that have never been applied to a routine test panel and it could be applicable in clinical decision making.
Conclusions
This systematic review showed that serum levels of adiponectin, leptin, ferritin, TGF-β1, and PDGF-BB could be affected by patients' gender, age, genetic diversity, and underlying hereditary or non-hereditary disorders and must be considered in future studies. Investigating the correlation between histological stage, liver tissue expression and serum levels of markers such as TGF-β1 and PDGF-BB could be helpful in the validation of the markers for the prediction of liver fibrosis or cirrhosis. It is interesting to note that the involved signaling pathways as well as events such as angiogenesis and collagen production could be useful in discovering drugable targets to prevent the progression of the liver fibrosis. Accordingly, analyzing the receptors of the proteins on the target cells is strongly recommended.
We conclude that serum levels of the markers, particularly ferritin, could successfully predict liver fibrosis/ cirrhosis, however, these data might not be clinically replicated and further studies are needed.
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